;PMID: 14513413
;source_file_2960.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..39] = [t:0..39]
;1)section:[e:40..57] = [t:40..57]
;2)section:[e:62..117] = [t:62..117]
;3)sentence:[e:121..270] = [t:121..270]
;4)section:[e:274..334] = [t:274..334]
;5)section:[e:338..478] = [t:338..478]
;6)sentence:[e:482..629] = [t:482..629]
;7)sentence:[e:630..812] = [t:630..812]
;8)sentence:[e:813..963] = [t:813..963]
;9)sentence:[e:964..1051] = [t:964..1051]
;10)sentence:[e:1052..1176] = [t:1052..1176]
;11)sentence:[e:1177..1259] = [t:1177..1259]
;12)sentence:[e:1261..1432] = [t:1261..1432]
;13)section:[e:1436..1472] = [t:1436..1472]
;14)section:[e:1476..1521] = [t:1476..1521]

;section 0 Span:0..39
;J Infect Dis.  2003 Oct 1;188(7):954-9.
(SEC
  (FRAG (NNP:[0..1] J) (NNP:[2..8] Infect) (NNP:[9..12] Dis) (.:[12..13] .)
        (CD:[15..19] 2003) (NNP:[20..23] Oct) (CD:[24..25] 1) (::[25..26] ;)
        (CD:[26..29] 188) (-LRB-:[29..30] -LRB-) (CD:[30..31] 7)
        (-RRB-:[31..32] -RRB-) (::[32..33] :) (CD:[33..38] 954-9) (.:[38..39] .)))

;section 1 Span:40..57
;Epub 2003 Sep 26.
(SEC
  (FRAG (NNP:[40..44] Epub) (CD:[45..49] 2003) (NNP:[50..53] Sep)
        (CD:[54..56] 26) (.:[56..57] .)))

;section 2 Span:62..117
;Comment in:      J Infect Dis. 2003 Oct 1;188(7):945-7.
(SEC
  (FRAG (NNP:[62..69] Comment) (IN:[70..72] in) (NNP:[72..73] :)
        (NNP:[79..80] J) (NNP:[81..87] Infect) (NNP:[88..91] Dis) (.:[91..92] .)
        (CD:[93..97] 2003) (NNP:[98..101] Oct) (CD:[102..103] 1)
        (::[103..104] ;) (CD:[104..107] 188) (NN:[107..108] -LRB-)
        (CD:[108..109] 7) (-RRB-:[109..110] -RRB-) (::[110..111] :)
        (CD:[111..116] 945-7) (.:[116..117] .)))

;sentence 3 Span:121..270
;Development of resistance to acyclovir during chronic infection with the Oka 
;vaccine strain of varicella-zoster virus, in an immunosuppressed child.
;[264..269]:malignancy-developmental-state:"child"
(SENT
  (NP-HLN
    (NP (NN:[121..132] Development))
    (PP (IN:[133..135] of)
      (NP
        (NP (NN:[136..146] resistance))
        (PP (TO:[147..149] to)
          (NP (NN:[150..159] acyclovir)))))
    (PP (IN:[160..166] during)
      (NP
        (NP (JJ:[167..174] chronic) (NN:[175..184] infection))
        (PP (IN:[185..189] with)
          (NP
            (NP (DT:[190..193] the)
              (NML (NN:[194..197] Oka) (NN:[199..206] vaccine))
              (NN:[207..213] strain))
            (PP (IN:[214..216] of)
              (NP
                (NML (NN:[217..226] varicella) (HYPH:[226..227] -)
                     (NN:[227..233] zoster))
                (NN:[234..239] virus)))))))
    (,:[239..240] ,)
    (PP (IN:[241..243] in)
      (NP (DT:[244..246] an) (VBN:[247..263] immunosuppressed)
          (NN:[264..269] child)))
    (.:[269..270] .)))

;section 4 Span:274..334
;Levin MJ, Dahl KM, Weinberg A, Giller R, Patel A, Krause PR.
(SEC
  (FRAG (NNP:[274..279] Levin) (NNP:[280..282] MJ) (,:[282..283] ,)
        (NNP:[284..288] Dahl) (NNP:[289..291] KM) (,:[291..292] ,)
        (NNP:[293..301] Weinberg) (NNP:[302..303] A) (,:[303..304] ,)
        (NNP:[305..311] Giller) (NNP:[312..313] R) (,:[313..314] ,)
        (NNP:[315..320] Patel) (NNP:[321..322] A) (,:[322..323] ,)
        (NNP:[324..330] Krause) (NNP:[331..333] PR) (.:[333..334] .)))

;section 5 Span:338..478
;Section of Pediatric Infectious Diseases, University of Colorado Health
;Sciences  Center, Denver, Colorado 80262, USA. myron.levin@uchsc.edu
(SEC
  (FRAG (NN:[338..345] Section) (IN:[346..348] of) (JJ:[349..358] Pediatric)
        (JJ:[359..369] Infectious) (NNP:[370..378] Diseases) (,:[378..379] ,)
        (NNP:[380..390] University) (IN:[391..393] of) (NNP:[394..402] Colorado)
        (NNP:[403..409] Health) (NNP:[410..418] Sciences)
        (NNP:[420..426] Center) (,:[426..427] ,) (NNP:[428..434] Denver)
        (,:[434..435] ,) (NNP:[436..444] Colorado) (CD:[445..450] 80262)
        (,:[450..451] ,) (NNP:[452..455] USA) (.:[455..456] .)
        ('':[457..478] myron.levin@uchsc.edu)))

;sentence 6 Span:482..629
;A 1-year-old boy was vaccinated with the Oka strain of varicella just prior
;to  the discovery of a tumor that required intensive antitumor therapy.
;[484..494]:malignancy-developmental-state:"1-year-old"
(SENT
  (S
    (NP-SBJ-1 (DT:[482..483] A)
      (ADJP (CD:[484..485] 1) (HYPH:[485..486] -) (NN:[486..490] year)
            (HYPH:[490..491] -) (JJ:[491..494] old))
      (NN:[495..498] boy))
    (VP (VBD:[499..502] was)
      (VP (VBN:[503..513] vaccinated)
        (NP-1 (-NONE-:[513..513] *))
        (PP (IN:[514..518] with)
          (NP
            (NP (DT:[519..522] the) (NN:[523..526] Oka) (NN:[527..533] strain))
            (PP (IN:[534..536] of)
              (NP
                (NP (NN:[537..546] varicella))
                (PP
                  (ADVP (RB:[547..551] just))
                  (JJ:[552..557] prior)
                  (PP (TO:[558..560] to)
                    (NP
                      (NP (DT:[562..565] the) (NN:[566..575] discovery))
                      (PP (IN:[576..578] of)
                        (NP
                          (NP (DT:[579..580] a) (NN:[581..586] tumor))
                          (SBAR
                            (WHNP-2 (WDT:[587..591] that))
                            (S
                              (NP-SBJ-2 (-NONE-:[591..591] *T*))
                              (VP (VBD:[592..600] required)
                                (NP (JJ:[601..610] intensive)
                                    (JJ:[611..620] antitumor)
                                    (NN:[621..628] therapy))))))))))))))))
    (.:[628..629] .)))

;sentence 7 Span:630..812
;Three months  later he developed herpes zoster, which developed into chronic
;verrucous lesions  that were refractory to treatment with acyclovir and which
;subsequently  disseminated.
;[707..724]:malignancy-type:"verrucous lesions"
;[799..811]:malignancy-clinical-stage:"disseminated"
(SENT
  (S
    (ADVP
      (NP (CD:[630..635] Three) (NNS:[636..642] months))
      (RB:[644..649] later))
    (NP-SBJ (PRP:[650..652] he))
    (VP (VBD:[653..662] developed)
      (NP
        (NP (NN:[663..669] herpes) (NN:[670..676] zoster))
        (,:[676..677] ,)
        (SBAR
          (WHNP-1 (WDT:[678..683] which))
          (S
            (NP-SBJ-1 (-NONE-:[683..683] *T*))
            (VP (VBD:[684..693] developed)
              (PP (IN:[694..698] into)
                (NP
                  (NP (JJ:[699..706] chronic)
                     (JJ:[707..716] verrucous) (NNS:[717..724] lesions))
                  (SBAR
                    (SBAR
                      (WHNP-2 (WDT:[726..730] that))
                      (S
                        (NP-SBJ-2 (-NONE-:[730..730] *T*))
                        (VP (VBD:[731..735] were)
                          (ADJP-PRD (JJ:[736..746] refractory)
                            (PP (TO:[747..749] to)
                              (NP
                                (NP (NN:[750..759] treatment))
                                (PP (IN:[760..764] with)
                                  (NP (NN:[765..774] acyclovir)))))))))
                    (CC:[775..778] and)
                    (SBAR
                      (WHNP-3 (WDT:[779..784] which))
                      (S
                        (NP-SBJ-3 (-NONE-:[784..784] *T*))
                        (ADVP (RB:[785..797] subsequently))
                        (VP (VBD:[799..811] disseminated))))))))))))
    (.:[811..812] .)))

;sentence 8 Span:813..963
;DNA from a biopsy specimen of a chronic herpes-zoster lesion  indicated that
;the Oka vaccine strain of the the virus caused this severe  complication.
;[845..873]:malignancy-type:"chronic herpes-zoster lesion"
(SENT
  (S
    (NP-SBJ
      (NP (NN:[813..816] DNA))
      (PP (IN:[817..821] from)
        (NP
          (NP (DT:[822..823] a) (NN:[824..830] biopsy) (NN:[831..839] specimen))
          (PP (IN:[840..842] of)
            (NP (DT:[843..844] a)
               (JJ:[845..852] chronic)
              (NML (NN:[853..859] herpes) (HYPH:[859..860] -)
                   (NN:[860..866] zoster))
              (NN:[867..873] lesion))))))
    (VP (VBD:[875..884] indicated)
      (SBAR (IN:[885..889] that)
        (S
          (NP-SBJ
            (NP (DT:[890..893] the) (NN:[894..897] Oka) (NN:[898..905] vaccine)
                (NN:[906..912] strain))
            (PP (IN:[913..915] of)
              (NP (DT:[916..919] the)
                (NP (DT:[920..923] the) (NN:[924..929] virus)))))
          (VP (VBD:[930..936] caused)
            (NP (DT:[937..941] this) (JJ:[942..948] severe)
                (NN:[950..962] complication))))))
    (.:[962..963] .)))

;sentence 9 Span:964..1051
;Analysis of this viral DNA demonstrated a mutation in the viral  thymidine
;kinase gene.
;[1029..1045]:gene-rna:"thymidine kinase"
(SENT
  (S
    (NP-SBJ
      (NP (NN:[964..972] Analysis))
      (PP (IN:[973..975] of)
        (NP (DT:[976..980] this) (JJ:[981..986] viral) (NN:[987..990] DNA))))
    (VP (VBD:[991..1003] demonstrated)
      (NP (DT:[1004..1005] a) (NN:[1006..1014] mutation))
      (PP-LOC (IN:[1015..1017] in)
        (NP (DT:[1018..1021] the) (JJ:[1022..1027] viral)
          (NML (NN:[1029..1038] thymidine) (NN:[1039..1045] kinase))
          (NN:[1046..1050] gene))))
    (.:[1050..1051] .)))

;sentence 10 Span:1052..1176
;Plasmids containing this altered gene were unable to  produce functional
;thymidine kinase in an in vitro translation system.
;[1125..1141]:gene-protein:"thymidine kinase"
(SENT
  (S
    (NP-SBJ
      (NP (NNS:[1052..1060] Plasmids))
      (VP (VBG:[1061..1071] containing)
        (NP (DT:[1072..1076] this) (VBN:[1077..1084] altered)
            (NN:[1085..1089] gene))))
    (VP (VBD:[1090..1094] were)
      (ADJP-PRD (JJ:[1095..1101] unable)
        (S
          (NP-SBJ (-NONE-:[1101..1101] *))
          (VP (TO:[1102..1104] to)
            (VP (VB:[1106..1113] produce)
              (NP (JJ:[1114..1124] functional)
                 (NN:[1125..1134] thymidine) (NN:[1135..1141] kinase))
              (PP (IN:[1142..1144] in)
                (NP (DT:[1145..1147] an)
                  (ADJP (FW:[1148..1150] in) (FW:[1151..1156] vitro))
                  (NN:[1157..1168] translation) (NN:[1169..1175] system))))))))
    (.:[1175..1176] .)))

;sentence 11 Span:1177..1259
;The  presence of this mutation would explain the clinical resistance to
;acyclovir.
(SENT
  (S
    (NP-SBJ
      (NP (DT:[1177..1180] The) (NN:[1182..1190] presence))
      (PP (IN:[1191..1193] of)
        (NP (DT:[1194..1198] this) (NN:[1199..1207] mutation))))
    (VP (MD:[1208..1213] would)
      (VP (VB:[1214..1221] explain)
        (NP
          (NP (DT:[1222..1225] the) (JJ:[1226..1234] clinical)
              (NN:[1235..1245] resistance))
          (PP (TO:[1246..1248] to)
            (NP (NN:[1249..1258] acyclovir))))))
    (.:[1258..1259] .)))

;sentence 12 Span:1261..1432
;This is the first report of Oka-strain varicella virus causing severe disease
; after reactivation and of resistance to acyclovir during an infection caused
;by  this virus.
(SENT
  (S
    (NP-SBJ (DT:[1261..1265] This))
    (VP (VBZ:[1266..1268] is)
      (NP
        (NP (DT:[1269..1272] the) (JJ:[1273..1278] first)
            (NN:[1279..1285] report))
        (PP
          (PP (IN:[1286..1288] of)
            (NP
              (NP
                (NML (NN:[1289..1292] Oka) (HYPH:[1292..1293] -)
                     (NN:[1293..1299] strain))
                (NN:[1300..1309] varicella) (NN:[1310..1315] virus))
              (VP (VBG:[1316..1323] causing)
                (NP (JJ:[1324..1330] severe) (NN:[1331..1338] disease))
                (PP-TMP (IN:[1340..1345] after)
                  (NP (NN:[1346..1358] reactivation))))))
          (CC:[1359..1362] and)
          (PP (IN:[1363..1365] of)
            (NP
              (NP
                (NP (NN:[1366..1376] resistance))
                (PP (TO:[1377..1379] to)
                  (NP (NN:[1380..1389] acyclovir)))
                (PP-TMP (IN:[1390..1396] during)
                  (NP (DT:[1397..1399] an) (NN:[1400..1409] infection))))
              (VP (VBN:[1410..1416] caused)
                (NP (-NONE-:[1416..1416] *))
                (PP (IN:[1417..1419] by)
                  (NP-LGS (DT:[1421..1425] this) (NN:[1426..1431] virus)))))))))
    (.:[1431..1432] .)))

;section 13 Span:1436..1472
;Publication Types:      Case Reports
(SEC
  (FRAG (NNP:[1436..1447] Publication) (NNP:[1448..1453] Types)
        (::[1453..1454] :) (NN:[1460..1464] Case) (NNS:[1465..1472] Reports)))

;section 14 Span:1476..1521
;PMID: 14513413 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1476..1480] PMID) (::[1480..1481] :) (CD:[1482..1490] 14513413)
        (NN:[1491..1492] -LSB-) (NNP:[1492..1498] PubMed) (::[1499..1500] -)
        (NN:[1501..1508] indexed) (IN:[1509..1512] for)
        (NNP:[1513..1520] MEDLINE) (-RRB-:[1520..1521] -RSB-)))
